BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
Identifieur interne : 000A97 ( Main/Exploration ); précédent : 000A96; suivant : 000A98BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
Auteurs : Marinus Van Hulst [Pays-Bas] ; Gijs A. A. Hubben [Pays-Bas] ; Kwamena W. C. Sagoe [Pays-Bas] ; Charupon Promwong [Pays-Bas] ; Parichart Permpikul [Pays-Bas] ; Ladda Fongsatitkul [Pays-Bas] ; Diarmuid M. Glynn [Pays-Bas] ; Cees T. Smit Sibinga [Pays-Bas] ; Maarten J. Postma [Pays-Bas]Source :
- Transfusion [ 0041-1132 ] ; 2009-12.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice, Banques de sang (), Banques de sang (économie), Contrôle des maladies contagieuses (), Contrôle des maladies contagieuses (économie), Donneurs de sang (), Facteurs de risque, Ghana (épidémiologie), Humains, Hépatite B (), Hépatite B (sang), Hépatite B (transmission), Hépatite C (), Hépatite C (sang), Hépatite C (transmission), Infections à VIH (), Infections à VIH (sang), Infections à VIH (transmission), Internet, Modèles économétriques, Pays-Bas (épidémiologie), Santé mondiale, Thaïlande (épidémiologie), Transfusion sanguine (), Transfusion sanguine (effets indésirables), Transfusion sanguine (économie), Transmission de maladie infectieuse (), Transmission de maladie infectieuse (économie), Évaluation des risques.
- MESH :
- effets indésirables : Transfusion sanguine.
- sang : Hépatite B, Hépatite C, Infections à VIH.
- économie : Banques de sang, Contrôle des maladies contagieuses, Hépatite B, Hépatite C, Infections à VIH, Transfusion sanguine, Transmission de maladie infectieuse.
- épidémiologie : Ghana, Pays-Bas, Thaïlande.
- Wicri :
- geographic : Analyse coût-bénéfice, Banques de sang, Contrôle des maladies contagieuses, Donneurs de sang, Facteurs de risque, Ghana, Humains, Hépatite B, Hépatite C, Infections à VIH, Internet, Modèles économétriques, Pays-Bas, Santé mondiale, Thaïlande, Transfusion sanguine, Transmission de maladie infectieuse, Évaluation des risques.
- topic : Transfusion sanguine, Don, Espérance de vie.
English descriptors
- KwdEn :
- Active antiretroviral therapy, Additional antigen screening, Additional health gains, Additional screening, Antibody screening, Antigen screening, Antigen testing, Antiretroviral therapy, Assay, Bangkok, Base case, Blood Banks (economics), Blood Banks (methods), Blood Donors (statistics & numerical data), Blood Transfusion (adverse effects), Blood Transfusion (economics), Blood Transfusion (statistics & numerical data), Blood banks, Blood donors, Blood transfusion, Blood transfusion recipients, Blood transfusion safety, Chronic hepatitis, Combo, Combo assays, Combo hbsag, Combo tests, Communicable Disease Control (economics), Communicable Disease Control (statistics & numerical data), Correction factor, Cost-Benefit Analysis, Costeffectiveness, Costeffectiveness analysis, Daly, Daly dalys, Daly icer, Dalys, December, Decision makers, Disability weight, Disease Transmission, Infectious (economics), Disease Transmission, Infectious (statistics & numerical data), Disease burden, Disease states, Donation, Donor, Dutch population, Economic assessment, Economic evaluation, Economic studies, Epidemiological fact sheets, Exact information requirements, Expensive screening strategy, Expert panel, Ghana, Ghana (epidemiology), Ghana thailand, Global Health, Global model, Greatest number, HIV Infections (blood), HIV Infections (prevention & control), HIV Infections (transmission), Hbsag, Hbsag positivity, Health care costs, Hepatitis, Hepatitis B (blood), Hepatitis B (prevention & control), Hepatitis B (transmission), Hepatitis C (blood), Hepatitis C (prevention & control), Hepatitis C (transmission), Hepatocellular carcinoma, Hospital mortality, Hulst, Human virus, Humans, Icer, Immunization coverage, Incidence rates, Incidence window period model, Incubation time, Individual donation, Infection, Infectious diseases, Interface, Internet, Labor costs, Life expectancy, Liver transplantation, Local conditions, Local decision makers, Many regions, Medical professionals, Models, Econometric, Multiplex, Netherlands, Netherlands (epidemiology), Netherlands thailand, Nucleic acid testing, Online version, Other screening strategies, Patient population, Postdonation screening, Regional scenarios, Replacement donors, Residual, Residual risk, Risk Assessment, Risk Factors, Risk assessment, Sanquin blood supply foundation, Scenario, Screening, Screening costs, Screening methods, Screening strategies, Screening strategy, Screening techniques, Small difference, Smit sibinga, Songkla, Standard care, Surface antigen, Systematic review, Teaching hospital, Test costs, Thai blood donations, Thailand, Thailand (epidemiology), Total costs, Training costs, Transfusion, Transfusion medicine, Transfusion recipients, Transfusion volume, Transmission risk, Transmission risk assessment, Transmission risk estimation, Transmission risks, Treatment costs, Unaids reference group, Variable estimates, Viral, Viral infections, Viral markers, Viral transmission, Virus infection, Window period, Window period model, World bank.
- MESH :
- geographic , epidemiology : Ghana, Netherlands, Thailand.
- adverse effects : Blood Transfusion.
- blood : HIV Infections, Hepatitis B, Hepatitis C.
- economics : Blood Banks, Blood Transfusion, Communicable Disease Control, Disease Transmission, Infectious.
- methods : Blood Banks.
- prevention & control : HIV Infections, Hepatitis B, Hepatitis C.
- statistics & numerical data : Blood Donors, Blood Transfusion, Communicable Disease Control, Disease Transmission, Infectious.
- transmission : HIV Infections, Hepatitis B, Hepatitis C.
- Teeft :
- Active antiretroviral therapy, Additional antigen screening, Additional health gains, Additional screening, Antibody screening, Antigen screening, Antigen testing, Antiretroviral therapy, Assay, Bangkok, Base case, Blood banks, Blood donors, Blood transfusion, Blood transfusion recipients, Blood transfusion safety, Chronic hepatitis, Combo, Combo assays, Combo hbsag, Combo tests, Correction factor, Cost-Benefit Analysis, Costeffectiveness, Costeffectiveness analysis, Daly, Daly dalys, Daly icer, Dalys, December, Decision makers, Disability weight, Disease burden, Disease states, Donation, Donor, Dutch population, Economic assessment, Economic evaluation, Economic studies, Epidemiological fact sheets, Exact information requirements, Expensive screening strategy, Expert panel, Ghana, Ghana thailand, Global Health, Global model, Greatest number, Hbsag, Hbsag positivity, Health care costs, Hepatitis, Hepatocellular carcinoma, Hospital mortality, Hulst, Human virus, Humans, Icer, Immunization coverage, Incidence rates, Incidence window period model, Incubation time, Individual donation, Infection, Infectious diseases, Interface, Internet, Labor costs, Life expectancy, Liver transplantation, Local conditions, Local decision makers, Many regions, Medical professionals, Models, Econometric, Multiplex, Netherlands, Netherlands thailand, Nucleic acid testing, Online version, Other screening strategies, Patient population, Postdonation screening, Regional scenarios, Replacement donors, Residual, Residual risk, Risk Assessment, Risk Factors, Risk assessment, Sanquin blood supply foundation, Scenario, Screening, Screening costs, Screening methods, Screening strategies, Screening strategy, Screening techniques, Small difference, Smit sibinga, Songkla, Standard care, Surface antigen, Systematic review, Teaching hospital, Test costs, Thai blood donations, Thailand, Total costs, Training costs, Transfusion, Transfusion medicine, Transfusion recipients, Transfusion volume, Transmission risk, Transmission risk assessment, Transmission risk estimation, Transmission risks, Treatment costs, Unaids reference group, Variable estimates, Viral, Viral infections, Viral markers, Viral transmission, Virus infection, Window period, Window period model, World bank.
Abstract
BACKGROUND: The goal of our research was to actively involve decision makers in the economic assessment of screening strategies in their region. This study attempted to accomplish this by providing an easy‐to‐use Web interface at http://www.bloodsafety.info that allows decision makers to adapt this model to local conditions.
Url:
DOI: 10.1111/j.1537-2995.2009.02351.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000064
- to stream Istex, to step Curation: 000064
- to stream Istex, to step Checkpoint: 000233
- to stream PubMed, to step Corpus: 000238
- to stream PubMed, to step Curation: 000238
- to stream PubMed, to step Checkpoint: 000238
- to stream Ncbi, to step Merge: 000340
- to stream Ncbi, to step Curation: 000340
- to stream Ncbi, to step Checkpoint: 000340
- to stream Main, to step Merge: 000B14
- to stream Main, to step Curation: 000A97
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands</title><author><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name></author><author><name sortKey="Hubben, Gijs A A" sort="Hubben, Gijs A A" uniqKey="Hubben G" first="Gijs A. A." last="Hubben">Gijs A. A. Hubben</name></author><author><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W. C." last="Sagoe">Kwamena W. C. Sagoe</name></author><author><name sortKey="Promwong, Charupon" sort="Promwong, Charupon" uniqKey="Promwong C" first="Charupon" last="Promwong">Charupon Promwong</name></author><author><name sortKey="Permpikul, Parichart" sort="Permpikul, Parichart" uniqKey="Permpikul P" first="Parichart" last="Permpikul">Parichart Permpikul</name></author><author><name sortKey="Fongsatitkul, Ladda" sort="Fongsatitkul, Ladda" uniqKey="Fongsatitkul L" first="Ladda" last="Fongsatitkul">Ladda Fongsatitkul</name></author><author><name sortKey="Glynn, Diarmuid M" sort="Glynn, Diarmuid M" uniqKey="Glynn D" first="Diarmuid M." last="Glynn">Diarmuid M. Glynn</name></author><author><name sortKey="Sibinga, Cees T Smit" sort="Sibinga, Cees T Smit" uniqKey="Sibinga C" first="Cees T. Smit" last="Sibinga">Cees T. Smit Sibinga</name></author><author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J." last="Postma">Maarten J. Postma</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E15E21570E72E7BEB8E6FEB43DDC8184F20A9EB9</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1537-2995.2009.02351.x</idno><idno type="url">https://api.istex.fr/document/E15E21570E72E7BEB8E6FEB43DDC8184F20A9EB9/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000064</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000064</idno><idno type="wicri:Area/Istex/Curation">000064</idno><idno type="wicri:Area/Istex/Checkpoint">000233</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000233</idno><idno type="wicri:doubleKey">0041-1132:2009:Van Hulst M:blood:donors:and</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19709093</idno><idno type="wicri:Area/PubMed/Corpus">000238</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000238</idno><idno type="wicri:Area/PubMed/Curation">000238</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000238</idno><idno type="wicri:Area/PubMed/Checkpoint">000238</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000238</idno><idno type="wicri:Area/Ncbi/Merge">000340</idno><idno type="wicri:Area/Ncbi/Curation">000340</idno><idno type="wicri:Area/Ncbi/Checkpoint">000340</idno><idno type="wicri:Area/Main/Merge">000B14</idno><idno type="wicri:Area/Main/Curation">000A97</idno><idno type="wicri:Area/Main/Exploration">000A97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands</title><author><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Hubben, Gijs A A" sort="Hubben, Gijs A A" uniqKey="Hubben G" first="Gijs A. A." last="Hubben">Gijs A. A. Hubben</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W. C." last="Sagoe">Kwamena W. C. Sagoe</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Promwong, Charupon" sort="Promwong, Charupon" uniqKey="Promwong C" first="Charupon" last="Promwong">Charupon Promwong</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Permpikul, Parichart" sort="Permpikul, Parichart" uniqKey="Permpikul P" first="Parichart" last="Permpikul">Parichart Permpikul</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Fongsatitkul, Ladda" sort="Fongsatitkul, Ladda" uniqKey="Fongsatitkul L" first="Ladda" last="Fongsatitkul">Ladda Fongsatitkul</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Glynn, Diarmuid M" sort="Glynn, Diarmuid M" uniqKey="Glynn D" first="Diarmuid M." last="Glynn">Diarmuid M. Glynn</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Sibinga, Cees T Smit" sort="Sibinga, Cees T Smit" uniqKey="Sibinga C" first="Cees T. Smit" last="Sibinga">Cees T. Smit Sibinga</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J." last="Postma">Maarten J. Postma</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>From the Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen; the Department of Clinical Pharmacy and Toxicology, Martini Hospital; and Health Economics Consultancy and Technology Assessments (HECTA), Groningen, The Netherlands; BaseCase GmbH Decision Support Software, Zug, Switzerland; the Department of Microbiology, University of Ghana Medical School, Accra, Ghana; the Blood Bank and Transfusion Medicine Unit, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand; the Department of Transfusion Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; the Blood Bank Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; and the Academic Institute for International Development of Transfusion Medicine, Sanquin Consulting Services and WHO Collaborating Centre for Blood Transfusion, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Transfusion</title><title level="j" type="alt">TRANSFUSION</title><idno type="ISSN">0041-1132</idno><idno type="eISSN">1537-2995</idno><imprint><biblScope unit="vol">49</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2729">2729</biblScope><biblScope unit="page" to="2742">2742</biblScope><biblScope unit="page-count">14</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2009-12">2009-12</date></imprint><idno type="ISSN">0041-1132</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0041-1132</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Active antiretroviral therapy</term><term>Additional antigen screening</term><term>Additional health gains</term><term>Additional screening</term><term>Antibody screening</term><term>Antigen screening</term><term>Antigen testing</term><term>Antiretroviral therapy</term><term>Assay</term><term>Bangkok</term><term>Base case</term><term>Blood Banks (economics)</term><term>Blood Banks (methods)</term><term>Blood Donors (statistics & numerical data)</term><term>Blood Transfusion (adverse effects)</term><term>Blood Transfusion (economics)</term><term>Blood Transfusion (statistics & numerical data)</term><term>Blood banks</term><term>Blood donors</term><term>Blood transfusion</term><term>Blood transfusion recipients</term><term>Blood transfusion safety</term><term>Chronic hepatitis</term><term>Combo</term><term>Combo assays</term><term>Combo hbsag</term><term>Combo tests</term><term>Communicable Disease Control (economics)</term><term>Communicable Disease Control (statistics & numerical data)</term><term>Correction factor</term><term>Cost-Benefit Analysis</term><term>Costeffectiveness</term><term>Costeffectiveness analysis</term><term>Daly</term><term>Daly dalys</term><term>Daly icer</term><term>Dalys</term><term>December</term><term>Decision makers</term><term>Disability weight</term><term>Disease Transmission, Infectious (economics)</term><term>Disease Transmission, Infectious (statistics & numerical data)</term><term>Disease burden</term><term>Disease states</term><term>Donation</term><term>Donor</term><term>Dutch population</term><term>Economic assessment</term><term>Economic evaluation</term><term>Economic studies</term><term>Epidemiological fact sheets</term><term>Exact information requirements</term><term>Expensive screening strategy</term><term>Expert panel</term><term>Ghana</term><term>Ghana (epidemiology)</term><term>Ghana thailand</term><term>Global Health</term><term>Global model</term><term>Greatest number</term><term>HIV Infections (blood)</term><term>HIV Infections (prevention & control)</term><term>HIV Infections (transmission)</term><term>Hbsag</term><term>Hbsag positivity</term><term>Health care costs</term><term>Hepatitis</term><term>Hepatitis B (blood)</term><term>Hepatitis B (prevention & control)</term><term>Hepatitis B (transmission)</term><term>Hepatitis C (blood)</term><term>Hepatitis C (prevention & control)</term><term>Hepatitis C (transmission)</term><term>Hepatocellular carcinoma</term><term>Hospital mortality</term><term>Hulst</term><term>Human virus</term><term>Humans</term><term>Icer</term><term>Immunization coverage</term><term>Incidence rates</term><term>Incidence window period model</term><term>Incubation time</term><term>Individual donation</term><term>Infection</term><term>Infectious diseases</term><term>Interface</term><term>Internet</term><term>Labor costs</term><term>Life expectancy</term><term>Liver transplantation</term><term>Local conditions</term><term>Local decision makers</term><term>Many regions</term><term>Medical professionals</term><term>Models, Econometric</term><term>Multiplex</term><term>Netherlands</term><term>Netherlands (epidemiology)</term><term>Netherlands thailand</term><term>Nucleic acid testing</term><term>Online version</term><term>Other screening strategies</term><term>Patient population</term><term>Postdonation screening</term><term>Regional scenarios</term><term>Replacement donors</term><term>Residual</term><term>Residual risk</term><term>Risk Assessment</term><term>Risk Factors</term><term>Risk assessment</term><term>Sanquin blood supply foundation</term><term>Scenario</term><term>Screening</term><term>Screening costs</term><term>Screening methods</term><term>Screening strategies</term><term>Screening strategy</term><term>Screening techniques</term><term>Small difference</term><term>Smit sibinga</term><term>Songkla</term><term>Standard care</term><term>Surface antigen</term><term>Systematic review</term><term>Teaching hospital</term><term>Test costs</term><term>Thai blood donations</term><term>Thailand</term><term>Thailand (epidemiology)</term><term>Total costs</term><term>Training costs</term><term>Transfusion</term><term>Transfusion medicine</term><term>Transfusion recipients</term><term>Transfusion volume</term><term>Transmission risk</term><term>Transmission risk assessment</term><term>Transmission risk estimation</term><term>Transmission risks</term><term>Treatment costs</term><term>Unaids reference group</term><term>Variable estimates</term><term>Viral</term><term>Viral infections</term><term>Viral markers</term><term>Viral transmission</term><term>Virus infection</term><term>Window period</term><term>Window period model</term><term>World bank</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Banques de sang ()</term><term>Banques de sang (économie)</term><term>Contrôle des maladies contagieuses ()</term><term>Contrôle des maladies contagieuses (économie)</term><term>Donneurs de sang ()</term><term>Facteurs de risque</term><term>Ghana (épidémiologie)</term><term>Humains</term><term>Hépatite B ()</term><term>Hépatite B (sang)</term><term>Hépatite B (transmission)</term><term>Hépatite C ()</term><term>Hépatite C (sang)</term><term>Hépatite C (transmission)</term><term>Infections à VIH ()</term><term>Infections à VIH (sang)</term><term>Infections à VIH (transmission)</term><term>Internet</term><term>Modèles économétriques</term><term>Pays-Bas (épidémiologie)</term><term>Santé mondiale</term><term>Thaïlande (épidémiologie)</term><term>Transfusion sanguine ()</term><term>Transfusion sanguine (effets indésirables)</term><term>Transfusion sanguine (économie)</term><term>Transmission de maladie infectieuse ()</term><term>Transmission de maladie infectieuse (économie)</term><term>Évaluation des risques</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ghana</term><term>Netherlands</term><term>Thailand</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Blood Transfusion</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Blood Banks</term><term>Blood Transfusion</term><term>Communicable Disease Control</term><term>Disease Transmission, Infectious</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transfusion sanguine</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Blood Banks</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hépatite B</term><term>Hépatite C</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Blood Donors</term><term>Blood Transfusion</term><term>Communicable Disease Control</term><term>Disease Transmission, Infectious</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term><term>Hepatitis C</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Banques de sang</term><term>Contrôle des maladies contagieuses</term><term>Hépatite B</term><term>Hépatite C</term><term>Infections à VIH</term><term>Transfusion sanguine</term><term>Transmission de maladie infectieuse</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ghana</term><term>Pays-Bas</term><term>Thaïlande</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Active antiretroviral therapy</term><term>Additional antigen screening</term><term>Additional health gains</term><term>Additional screening</term><term>Antibody screening</term><term>Antigen screening</term><term>Antigen testing</term><term>Antiretroviral therapy</term><term>Assay</term><term>Bangkok</term><term>Base case</term><term>Blood banks</term><term>Blood donors</term><term>Blood transfusion</term><term>Blood transfusion recipients</term><term>Blood transfusion safety</term><term>Chronic hepatitis</term><term>Combo</term><term>Combo assays</term><term>Combo hbsag</term><term>Combo tests</term><term>Correction factor</term><term>Cost-Benefit Analysis</term><term>Costeffectiveness</term><term>Costeffectiveness analysis</term><term>Daly</term><term>Daly dalys</term><term>Daly icer</term><term>Dalys</term><term>December</term><term>Decision makers</term><term>Disability weight</term><term>Disease burden</term><term>Disease states</term><term>Donation</term><term>Donor</term><term>Dutch population</term><term>Economic assessment</term><term>Economic evaluation</term><term>Economic studies</term><term>Epidemiological fact sheets</term><term>Exact information requirements</term><term>Expensive screening strategy</term><term>Expert panel</term><term>Ghana</term><term>Ghana thailand</term><term>Global Health</term><term>Global model</term><term>Greatest number</term><term>Hbsag</term><term>Hbsag positivity</term><term>Health care costs</term><term>Hepatitis</term><term>Hepatocellular carcinoma</term><term>Hospital mortality</term><term>Hulst</term><term>Human virus</term><term>Humans</term><term>Icer</term><term>Immunization coverage</term><term>Incidence rates</term><term>Incidence window period model</term><term>Incubation time</term><term>Individual donation</term><term>Infection</term><term>Infectious diseases</term><term>Interface</term><term>Internet</term><term>Labor costs</term><term>Life expectancy</term><term>Liver transplantation</term><term>Local conditions</term><term>Local decision makers</term><term>Many regions</term><term>Medical professionals</term><term>Models, Econometric</term><term>Multiplex</term><term>Netherlands</term><term>Netherlands thailand</term><term>Nucleic acid testing</term><term>Online version</term><term>Other screening strategies</term><term>Patient population</term><term>Postdonation screening</term><term>Regional scenarios</term><term>Replacement donors</term><term>Residual</term><term>Residual risk</term><term>Risk Assessment</term><term>Risk Factors</term><term>Risk assessment</term><term>Sanquin blood supply foundation</term><term>Scenario</term><term>Screening</term><term>Screening costs</term><term>Screening methods</term><term>Screening strategies</term><term>Screening strategy</term><term>Screening techniques</term><term>Small difference</term><term>Smit sibinga</term><term>Songkla</term><term>Standard care</term><term>Surface antigen</term><term>Systematic review</term><term>Teaching hospital</term><term>Test costs</term><term>Thai blood donations</term><term>Thailand</term><term>Total costs</term><term>Training costs</term><term>Transfusion</term><term>Transfusion medicine</term><term>Transfusion recipients</term><term>Transfusion volume</term><term>Transmission risk</term><term>Transmission risk assessment</term><term>Transmission risk estimation</term><term>Transmission risks</term><term>Treatment costs</term><term>Unaids reference group</term><term>Variable estimates</term><term>Viral</term><term>Viral infections</term><term>Viral markers</term><term>Viral transmission</term><term>Virus infection</term><term>Window period</term><term>Window period model</term><term>World bank</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Banques de sang</term><term>Contrôle des maladies contagieuses</term><term>Donneurs de sang</term><term>Facteurs de risque</term><term>Ghana</term><term>Humains</term><term>Hépatite B</term><term>Hépatite C</term><term>Infections à VIH</term><term>Internet</term><term>Modèles économétriques</term><term>Pays-Bas</term><term>Santé mondiale</term><term>Thaïlande</term><term>Transfusion sanguine</term><term>Transmission de maladie infectieuse</term><term>Évaluation des risques</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Transfusion sanguine</term><term>Don</term><term>Espérance de vie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">BACKGROUND: The goal of our research was to actively involve decision makers in the economic assessment of screening strategies in their region. This study attempted to accomplish this by providing an easy‐to‐use Web interface at http://www.bloodsafety.info that allows decision makers to adapt this model to local conditions.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country><region><li>Groningue (province)</li></region><settlement><li>Groningue</li></settlement></list><tree><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Van Hulst, Marinus" sort="Van Hulst, Marinus" uniqKey="Van Hulst M" first="Marinus" last="Van Hulst">Marinus Van Hulst</name></region><name sortKey="Fongsatitkul, Ladda" sort="Fongsatitkul, Ladda" uniqKey="Fongsatitkul L" first="Ladda" last="Fongsatitkul">Ladda Fongsatitkul</name><name sortKey="Glynn, Diarmuid M" sort="Glynn, Diarmuid M" uniqKey="Glynn D" first="Diarmuid M." last="Glynn">Diarmuid M. Glynn</name><name sortKey="Hubben, Gijs A A" sort="Hubben, Gijs A A" uniqKey="Hubben G" first="Gijs A. A." last="Hubben">Gijs A. A. Hubben</name><name sortKey="Permpikul, Parichart" sort="Permpikul, Parichart" uniqKey="Permpikul P" first="Parichart" last="Permpikul">Parichart Permpikul</name><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J." last="Postma">Maarten J. Postma</name><name sortKey="Promwong, Charupon" sort="Promwong, Charupon" uniqKey="Promwong C" first="Charupon" last="Promwong">Charupon Promwong</name><name sortKey="Sagoe, Kwamena W C" sort="Sagoe, Kwamena W C" uniqKey="Sagoe K" first="Kwamena W. C." last="Sagoe">Kwamena W. C. Sagoe</name><name sortKey="Sibinga, Cees T Smit" sort="Sibinga, Cees T Smit" uniqKey="Sibinga C" first="Cees T. Smit" last="Sibinga">Cees T. Smit Sibinga</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E15E21570E72E7BEB8E6FEB43DDC8184F20A9EB9
|texte= BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands
}}
| This area was generated with Dilib version V0.6.31. |  |